Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients
Information source: Saitama Medical University
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Candesartan (Drug); Telmisartan (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Saitama Medical University Official(s) and/or principal investigator(s): Hidetomo Nakamoto, MD, Principal Investigator, Affiliation: Saitama Medical School Department of Renal Medicine
Overall contact: Hidetomo Nakamoto, MD, Phone: +81-0492-76-1258, Email: nakamo_h@saitama-med.ac.jp
Summary
To investigate the effects of Candesartan and Telmisartan on the home blood pressure,
glucose and lipid-metabolism in the hypertensive patients with the accumulation of visceral
fat by the newly developed Tele-medicine system
Clinical Details
Official title: A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Primary outcome: Home blood pressure in the early morning
Secondary outcome: Home blood pressure at bedtimeM/E ratio Casual blood pressure Body fat percentage Body weight Height BMI Blood potassium Total cholesterol HDL cholesterol LDL cholesterol Triglyceride Blood glucose IRI HbAlc* HOMA-IR Urinary trace albumin Creatinine
Detailed description:
A randomized, comparative study of the effects of Candesartan and Telmisartan on the home
blood pressure, glucose and lipid metabolism in the hypertensive patients with the
accumulation of visceral fat by the central registration system
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Circumference at waist: male ≧85 cm, female ≧90 cm
- Hypertensive patient with untreated hypertension, and casual blood pressure of
systole ≧140 mmHg, or diastole ≧90 mmHg
- Hypertensive patient with hypertension under treatment, and casual blood pressure of
systole ≧130 mmHg, or diastole ≧85 mmHg
Exclusion Criteria:
- Significant hypertensive patient with diastolic blood pressure ≧120 mmHg
- Malignant hypertensive patient
- Patient with a contraindication to the study drugs (hypersensitivity, significant
hepatic diseases, pregnant woman)
- Patient with urinary protein (qualitative) +~++
- Patient with familial hyperlipidemia
- Other patients judged as ineligible for the study
Locations and Contacts
Hidetomo Nakamoto, MD, Phone: +81-0492-76-1258, Email: nakamo_h@saitama-med.ac.jp
Saitama Medical School Department of Renal Medicine, Saitama City, Saitama 350-0495, Japan; Recruiting Hidetomo Nakamoto, MD, Phone: +81-492-76-1258, Email: nakamo_h@saitama-med.ac.jp Hidetomo Nakamoto, MD, Principal Investigator
Additional Information
Starting date: February 2006
Last updated: January 9, 2007
|